期刊文献+

Comparison of antileukemic immunity mediated by dendritic cells derived from multidrug resistant leukemia K562/A02 cells and sensitive K562 cells 被引量:2

Comparison of antileukemic immunity mediated by dendritic cells derived from multidrug resistant leukemia K562/A02 cells and sensitive K562 cells
原文传递
导出
摘要 Dendritic cells (DCs), as the most potent antigen presenting cells in vivo, are central to generating specific immune responses and can be used as important vectors in antitumour immunity.~1 DCs loaded with tumour antigens can induce specific antitumour response in cytotoxic T lymphocytes (CTL). P-glycoprotein (P-gp), a product of mdr1 gene, widely overexpressed in many multidrug resistant (MDR) tumour cells, is a main mechanism that makes tumour cells escape from death induced by chemotherapeutic agents. However, this drug efflux protein may also be regarded as the antigen to active cellular immunity. It has been demonstrated that Dendritic cells (DCs), as the most potent antigen presenting cells in vivo, are central to generating specific immune responses and can be used as important vectors in antitumour immunity.~1 DCs loaded with tumour antigens can induce specific antitumour response in cytotoxic T lymphocytes (CTL). P-glycoprotein (P-gp), a product of mdr1 gene, widely overexpressed in many multidrug resistant (MDR) tumour cells, is a main mechanism that makes tumour cells escape from death induced by chemotherapeutic agents. However, this drug efflux protein may also be regarded as the antigen to active cellular immunity. It has been demonstrated that
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2005年第7期595-597,共3页 中华医学杂志(英文版)
基金 ThisstudywassupportedbytheNaturalScienceFoundationof GansuProvince(No.3ZS041A25061).
关键词 dendritic cells multidrug resistance P-GLYCOPROTEIN LEUKEMIA IMMUNITY dendritic cells · multidrug resistance · P-glycoprotein · leukemia · immunity
  • 相关文献

参考文献8

  • 1ZhangJ,ZhangJR,WangSM,etal.CD3AKandLAK’ssusceptibilityandmulti drugresistanceinKBandKBv200cellline[].ChinJMicrobiolImmunol.2001
  • 2AzumaE,MasudaS,QiJ,etal.CytotoxicT lymphocytes recognizineP glycoproteininmurinemultidrug$Cresistantleukemias[].EurJHaematol.1997
  • 3Savas B,Kerr PE,Ustun H,et al.Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma[].Anticancer Research.1998
  • 4Mohty M,Gaugler B,Calmels B,et al.Immunotherapy of acute myeloid leukemias: development of vaccines and cell therapy approaches[].Bulletin du Cancer.2003
  • 5Vuillier F,Dighiero G.Cell therapy by dendritic cells in chronic lymphoid leukemia: state of the art[].Bulletin du Cancer.2003
  • 6Yasukawa M,Ohminami H,Kojima K,et al.HLA class Ⅱ-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4+ T lymphocytes[].Blood.2001
  • 7Duan Z,Feller AJ,Toh HC,et al.TRAG-3, a novel gene,isolated from a taxol resistant ovarian carcinoma cell line[].Gene.1999
  • 8Calio C.Why are dendritic cells central to cancer immunotherapy[].Molecular Medicine Today.1999

同被引文献7

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部